Boston Scientific’s shares tumble 18% despite strong FY25 growth

Despite reporting gross of $20bn successful its fiscal twelvemonth 2025 (FY25) and beardown maturation successful Q4 2025, Boston Scientific’s shares took a deed astatine marketplace unfastened aft the merchandise of its financials.

Boston released its year-end results up of marketplace unfastened connected 4 February. The company’s shares connected the Nasdaq banal speech were trading astatine $81.38 astatine marketplace unfastened connected 4 February, a 11% driblet from a $91.62 per stock adjacent connected 3 February. Share prices fell by a further 7.2% by marketplace adjacent connected 4 February. Boston has a marketplace headdress astir $111.9bn.

In Q4 2025, Boston achieved gross of $5.2bn, indicative of a 15.9% uptick connected Q4 2024. The bulk of the quarter’s profits came via income successful Boston’s cardiovascular portfolio astatine $3.4bn, corresponding to an 18.2% emergence connected Q4 2024. Meanwhile, for FY25, cardiovascular contributed $13.3bn to the supra $20bn full for the year, representing a maturation borderline of 23.2% versus $10.8bn for the vertical successful FY24.

In spite of this performance, the marketplace seemingly homed successful connected level sales, comparative to Q3 2025, successful Boston’s electrophysiology (EP) and Watchman segments wrong its cardiovascular portfolio.

Boston’s EP segment, which includes its Farapulse pulsed-field ablation (PFA) system, drew successful full planetary Q4 revenues of $890m, representing YoY maturation of 37.1%. However, this fig was level connected a quarter-by-quarter basis, with Q3 2025’s income totalling $865m. Electrophysiology systems, similar Farapulse, are seen arsenic a large maturation operator for the institution fixed the size of the atrial fibrillation market.

Meanwhile, Boston’s Watchman franchise achieved full Q4 income of $535m.And portion the full fig represents a 29.4% uplift connected Q4 2024, it represents lone a humble ascent from $512m successful full income successful Q3 2025. For some the EP and Watchman segments, the US was the largest market.

Looking up to 2026, Boston expects to execute maturation of successful the 10.5% to 11.5% range, with net betwixt $3.43 and $3.49 per share. The institution outlined that successful 2026, it expects 15% maturation successful the EP market.

During a league call, analysts questioned what happened successful Q4 vis-à-vis Boston’s expectations versus those of the market, highlighting capitalist concerns implicit level EP and Watchman income fixed they contiguous 2 of Boston’s cardinal maturation drivers. With respect to the EP market, Mahoney commented that the institution placed much blimpish numbers connected its wide maturation successful precocious 2025.

Boston CEO Mike Mahoney said: “We deliberation the marketplace successful Q4 was person to 18% to 20% maturation alternatively than immoderate different companies’ assertion that it was 25%. We deliberation the marketplace was successful the 18% to 20% range, akin to what we developed internally successful our plan. We've called the marketplace for 2026 astatine astir 15% growth. We deliberation it's an fantabulous market, but we don't deliberation it grew 25% successful the 4th quarter.”